Canine Cancer: Supportive and Adjunct Care
Neoplasia in dogs, Cancer supportive care, Palliative and supportive oncology care, Adjunct care during chemotherapy, Cancer pain and appetite management
Cancer means a group of your dog's own cells has started growing when it should not. There are many different kinds and they behave very differently - some are cured by a single surgery, and others cannot be cured but can be slowed down for months or longer. This page is not about which cancer treatment to choose. It is about the care that runs alongside whatever your dog's team decides: keeping pain controlled, keeping her eating, keeping nausea away, and honestly checking whether she is having more good days than bad. That supportive care is not a consolation prize. It is the part of the plan that decides how your dog actually feels day to day, and there are real approved medicines for it.
What you might notice
- A new lump or swelling anywhere, or an old lump that has changed size, shape, firmness or colour
- A sore, scab or ulcer that keeps not healing, or a lump that bleeds or oozes
- Losing weight without you changing the food, or the muscle over the back and hind legs feeling thinner
- Going off food, eating more slowly, or becoming fussy about food she used to love
- Tiredness that does not fit - sleeping more, not wanting the usual walk, slower to get up and greet you
- Limping that gets worse rather than better, or a swollen painful spot on a leg bone
- Trouble breathing, a cough that will not clear, or getting out of breath on short walks
- Bad breath, drooling, bleeding from the mouth, or dropping food while eating
- Straining or changes in going to the toilet - blood in the urine or stool, or difficulty passing either
Standard of care
Get a tissue diagnosis, grade and stage before starting anything - including before starting steroids
Approved / guideline-backedCytology or histology or both, then grade, then stage with imaging and lymph node sampling. The practical trap in primary care is starting an anti-inflammatory or immunosuppressive dose of prednisone in a dog with enlarged lymph nodes or an undiagnosed mass because the owner wants something done today. That can render the diagnostic sample uninterpretable and forfeit the information the whole plan depends on. If the owner needs the dog to be comfortable while the sample is processed, reach for analgesia and antiemesis, not corticosteroid.
Named products: No drug. This step is the decision to withhold empirical treatment until there is a diagnosis.
Guideline position, both editions. AAHA 2016: 'Determination of tumor type by histologic examination of a biopsy sample should be the basis for all subsequent steps in oncology case management.' AAHA 2026: 'Therapy is based on identifying the tumor type, grade, and stage by using cytologic or histologic evaluation or both, combined with staging diagnostic testing such as imaging and lymph node sampling.' Note for honesty: the specific claim that corticosteroid pretreatment induces chemotherapy resistance in canine lymphoma is commonly taught but a primary citation for it was NOT located in this research pass - do not publish it as sourced. The diagnostic-obscuring point follows directly from the guideline principle and is safe to state.
Treat the cancer itself with the modality the tumour type calls for - supportive care is added to that, never substituted for it
Approved / guideline-backedSurgery, radiation therapy, chemotherapy and immunotherapy, usually in combination, chosen by type, grade and stage. Several canine-specific agents carry real approvals and real numbers. TANOVEA (rabacfosadine for injection), NADA 141-545, VetDC Inc., fully FDA-approved 15 July 2021 after conditional approval in December 2016, for the treatment of lymphoma in dogs: in the placebo-controlled field study, median progression-free survival was 82 days on TANOVEA (112 dogs) versus 21 days on saline placebo (36 dogs); in responders median PFS was 151 days, and 168 days in complete responders. STELFONTA (tigilanol tiglate injection), NADA 141-541, registered by QBiotics and distributed by Virbac, for non-metastatic cutaneous mast cell tumours and non-metastatic subcutaneous mast cell tumours located at or distal to the elbow or hock: at 28 days after a single intratumoral injection, 60/80 (75%) of treated dogs achieved a complete response versus 2/38 (5.3%) of untreated controls (p<0.0001), with an objective response in 64/80 (80%). Palladia (toceranib phosphate), NADA 141-295, is approved for canine mast cell tumours. Laverdia-CA1 (verdinexor) is a conditionally approved oral treatment for canine lymphoma. This is the one part of the veterinary market where 'targeted' and 'biologic' language is genuinely earned, and it is earned by drugs that went through the approval process.
Named products: Rabacfosadine (TANOVEA), NADA 141-545, dogs, lymphoma. Tigilanol tiglate (STELFONTA), NADA 141-541, dogs, non-metastatic mast cell tumour. Toceranib phosphate (Palladia), NADA 141-295, dogs, mast cell tumour. Verdinexor (Laverdia-CA1), conditionally approved, dogs, lymphoma. Oncept canine melanoma vaccine is USDA-licensed, not FDA-approved - see the safety section, because its efficacy is contested.
Tier 1 on two counts. Guideline: AAHA 2026 states therapy is most often multimodal and may include chemotherapy, immunotherapy, radiation therapy and surgery, along with nutritional support and pain management. Regulatory: the TANOVEA and STELFONTA numbers above are from the FDA Freedom of Information Summary and the FDA-approved label respectively, read directly, not from secondary reporting.
Control pain proactively and multimodally - and do not reach for an osteoarthritis product to do it
Approved / guideline-backedThe 2022 AAHA Pain Management Guidelines position is proactive, preemptive, multimodal analgesia with a tiered decision tree that prioritises the most efficacious modalities, and the AAHA Oncology Guidelines name pain management as an adjunctive modality in the treatment plan itself. In practice for cancer that means: an NSAID where renal, hepatic and GI status and concurrent corticosteroid use permit it; an opioid layer for breakthrough and for procedural pain; adjuncts such as gabapentin or amantadine for the neuropathic and central components; local and regional techniques around surgery; and physical measures - traction, bedding, shortened walks, ramps. Important scope limit that is being got wrong in the market: bedinvetmab (Librela) is FDA-approved for the control of osteoarthritis pain in dogs. It has no cancer-pain indication and no cancer-pain trial was located. Do not present an anti-NGF monoclonal as a cancer analgesic, and do not let its availability substitute for an actual analgesic plan.
Named products: FDA-approved canine NSAIDs and analgesics include carprofen, meloxicam, deracoxib, firocoxib, robenacoxib and grapiprant. Opioids, gabapentin and amantadine are used in dogs off-label or under species-specific approvals that were not individually verified in this pass. Bedinvetmab (Librela) is approved for osteoarthritis pain ONLY - not cancer pain.
Tier 1 guideline. Gruen et al. 2022 AAHA Pain Management Guidelines for Dogs and Cats provide the tiered multimodal framework. AAHA Oncology Guidelines 2026 place pain management inside the therapeutic plan rather than after it. No randomised trial of any specific analgesic protocol restricted to dogs with cancer pain was located in this pass - the evidence is guideline-level and extrapolated from chronic and perioperative canine pain, and should be described that way.
Prevent chemotherapy-induced vomiting rather than treating it - maropitant, given before the drug
Approved / guideline-backedMaropitant is a neurokinin-1 receptor antagonist and is FDA-approved in dogs (Cerenia, Zoetis, injection and tablets). The pivotal in-species data are in tumour-bearing dogs, not laboratory beagles, which is unusual and worth knowing. In a randomised clinical trial of 122 tumour-bearing dogs receiving cisplatin, dogs given maropitant BEFORE cisplatin in a prevention regimen did not vomit in 94.9% of cases versus 4.9% of placebo-treated dogs, and those that did vomit had significantly fewer emetic events (P<0.0001). Dogs given maropitant AFTER the first emetic event had significantly fewer subsequent events than placebo (P=0.0005), and 5.3% were withdrawn for treatment failure versus 56.4% on placebo. The clinical instruction is therefore prophylaxis, not rescue. Maropitant also outperformed ondansetron in a blinded crossover emesis-prevention study in dogs, where no dog vomited after maropitant versus 5/8 after ondansetron and 5/8 after saline.
Named products: Maropitant citrate (Cerenia, Zoetis Inc.), injection and tablet, FDA-approved for dogs. Ondansetron is used in dogs off-label and performed no better than saline in the one controlled canine emesis-prevention comparison located.
Tier 1: FDA-approved in dogs plus a randomised clinical trial in the target population. Vail et al. 2007, n=122 client-owned tumour-bearing dogs, three arms, cisplatin-induced emesis, prevention and treatment regimens. Corroborated in a controlled laboratory dose-ranging study (de la Puente-Redondo et al. 2007, 64 beagles) and in a head-to-head crossover against ondansetron (Kantyka et al. 2020, 8 beagles). Honest limit: the Vail trial was cisplatin-specific; comparable prevention data for every other cytotoxic protocol was not located. NADA number for Cerenia was NOT verified in this pass - state 'FDA-approved' and do not print a number.
Defend food intake and body weight - and never put a cancer patient on a weight-loss plan
Approved / guideline-backedWeight and muscle loss in a dog with cancer is not the same problem as obesity and must not be managed with restriction. Record body weight, body condition score and muscle condition score at every visit. Address the fixable causes of inappetence first - pain, nausea, oral disease, constipation, the taste of a medication. Then use a licensed appetite stimulant rather than coaxing. Capromorelin (ENTYCE) is a ghrelin receptor agonist and the first drug of its class developed for appetite stimulation in any species; it is FDA-approved as an oral solution for dogs. In a prospective, randomised, masked, placebo-controlled multicentre study of 244 client-owned dogs reported inappetent for at least two days (177 in the effectiveness analysis), owner-assessed appetite improved by day 3 in 68.6% (95% CI 59.7-76.3) on capromorelin versus 44.6% (32.2-57.8) on placebo (P=.008), and mean body weight rose 1.8% versus 0.1% (P<.001). Adverse reactions in more than 5% of either group were diarrhoea and vomiting.
Named products: Capromorelin oral solution (ENTYCE), FDA-approved for appetite stimulation in dogs. Therapeutic and highly palatable diets, feeding-tube placement where indicated. Mirtazapine is used in dogs off-label; no canine randomised trial for it was located in this pass. Do NOT prescribe a calorie-restricted or weight-management diet to a dog losing weight with cancer.
Tier 1: FDA-approved in dogs with a randomised placebo-controlled multicentre clinical study in client-owned dogs, supported by a randomised masked laboratory study in 24 beagles where food consumption rose 60.55% versus -11.15% on placebo (P<0.001). Two honest limits that matter here. First, the pivotal population was dogs inappetent from MIXED causes, not a tumour-bearing population, so the effect size in cancer cachexia specifically is an extrapolation. Second, capromorelin is a growth hormone secretagogue: whether raising the GH/IGF-1 axis has any consequence in a dog with a proliferative disease was NOT addressed by these trials and no study addressing it was located. That is a real question to raise with the attending oncologist, not a reason to withhold a licensed drug from a dog that is not eating. NADA number for ENTYCE was NOT verified in this pass.
Monitor for myelosuppression and grade every adverse event formally
Approved / guideline-backedA CBC before each cytotoxic dose, and a low threshold for a CBC in any chemotherapy patient that becomes dull, febrile, vomiting or diarrhoeic between doses. Grade what you find against VCOG-CTCAE v2 rather than describing it in free text - the grading structure was built to drive dose-limiting decisions, so it is the language in which dose reduction and dose delay are correctly argued. The TANOVEA registration file is a good worked example: across three studies the reported adverse reactions were graded on VCOG-CTCAE, most were grade 1 or 2, and dose reduction from 1 mg/kg to 0.8 and then 0.66 mg/kg or dose delay was the labelled management strategy. Teach owners the between-visit red flags in writing, not verbally.
Named products: No drug. CBC with differential, platelet count. Antimicrobial choice in febrile neutropenia should follow local culture and stewardship policy; no canine randomised trial of prophylactic antibiotics in chemotherapy-induced neutropenia was located in this pass, so do not publish a named protocol.
Tier 1 for the monitoring principle, which is guideline-level in AAHA 2026 (patient supportive care and follow-up assessments) and built into the labelled use of the approved canine cytotoxics. VCOG-CTCAE v2 is a consensus criteria document, not an efficacy trial - it is infrastructure, and it is the right infrastructure.
Use coarsely fractionated palliative radiation for bone pain - and quote its real duration and its real fracture rate
Early evidenceFor painful appendicular osteosarcoma in a dog whose owner has declined or cannot pursue amputation, hypofractionated palliative radiation is a legitimate and commonly used pain intervention. A retrospective series of 14 dogs given 10 Gy on each of two consecutive days (20 Gy total) reported subjectively improved pain control in 92.8% within a median of 14 days, with a median duration of response of 80 days (range 20-365). Toxicity was mostly VRTOG grade 1, principally alopecia. Five of 14 dogs (35.7%) developed a pathological fracture after treatment, at 24 to 250 days. Thirteen of the 14 also received pamidronate and an NSAID, and nine received adjuvant carboplatin, so the radiation effect cannot be isolated. Quote all four of those numbers together - the response rate without the fracture rate is a misleading claim.
Named products: No drug. External-beam radiation, 10 Gy x 2 consecutive daily fractions in the cited series.
Tier 3 by design: retrospective, descriptive, n=14, subjective pain assessment, concurrent pamidronate and NSAID in 13/14 and carboplatin in 9/14. It is real in-species clinical data on the actual indication, and it is weak. Present it as a reasonable option with a measured expectation, not as an established standard.
Know that adjuvant pamidronate failed its randomised test for pain - do not sell it as an analgesic
Controlled trial in this speciesAminobisphosphonates are mechanistically attractive in malignant osteolysis and are widely used. The best in-species test of the pain claim is negative. In a randomised, prospective, double-blinded, placebo-controlled trial, 50 dogs with appendicular osteosarcoma received standardised palliative therapy plus either pamidronate (n=26) or sterile saline (n=24). Median duration of subjective pain relief was 76 days with pamidronate and 75 days with placebo (P=.39). Forty percent of dogs in both arms combined achieved durable analgesia of 112 days or more, and the split was 11/26 pamidronate versus 9/24 placebo. The authors' own conclusion is that combining pamidronate with standardised palliative therapy is safe but 'does not clearly improve pain alleviation.' In the subset that did achieve durable pain control, pamidronate did produce greater reductions in urinary N-telopeptide excretion and larger increases in relative bone mineral density than placebo - a real biological effect that did not convert into a clinical pain benefit. An earlier uncontrolled prospective study of 43 dogs on pamidronate plus an NSAID found pain alleviation beyond 4 months in only 12/43 (28%).
Named products: Pamidronate disodium, intravenous, used off-label in dogs. Retain it, if at all, for the bone-turnover indication its own trial supports, not for pain.
Tier 2, and the direction of the result is negative. Randomised, double-blinded, placebo-controlled, n=50, in the target species with the target disease. This is stronger evidence than almost anything in the regenerative category and it says the adjunct does not work for the thing it is sold for. Publishing this is the honest position and it is also the differentiating one.
Consider an omega-3-enriched diet as a nutritional adjunct - stated at the strength the trial actually supports
Controlled trial in this speciesThis is the nutritional adjunct with the best canine oncology data, and the data are narrower than the way they are usually quoted. Thirty-two dogs with lymphoblastic lymphoma treated with doxorubicin were randomised, double-blind, to a diet supplemented with menhaden fish oil and arginine or an otherwise identical soybean-oil diet. Dogs on the experimental diet had significantly higher serum DHA (C22:6) and EPA (C20:5), and higher levels of those fatty acids were associated with smaller plasma lactic acid responses to glucose and diet tolerance testing. The survival finding is a within-arm dose-response association in a stage subgroup: increasing C22:6 levels were significantly associated with longer disease-free interval and survival time in dogs with STAGE III lymphoma fed the experimental diet. That is not the same claim as 'fish oil extends survival in canine lymphoma,' and the difference matters. Separately, omega-3-enriched diets and omega-3 supplements showed evident clinical analgesic efficacy in a PROSPERO-registered systematic review and meta-analysis of 72 trials in dogs and cats for osteoarthritis pain - a different indication, correctly labelled.
Named products: No drug. Marine-source omega-3 (EPA/DHA) enriched therapeutic diet, or a pharmaceutical-grade fish oil supplement dosed by the attending veterinarian. Watch total fat tolerance and platelet function around surgery.
Tier 2 with a stated caveat. Double-blind randomised placebo-controlled, n=32, correct species and a real cancer indication, but the survival signal is a subgroup dose-response association rather than a group-level primary endpoint win, and n=32 is small. The analgesic omega-3 evidence is tier 1-2 but for osteoarthritis, not cancer.
Measure quality of life on a validated instrument, at fixed intervals, and write down the stopping rule before you need it
Controlled trial in this speciesQuality of life is what owners actually optimise for, and it is the outcome most vulnerable to wishful recall. In a study of 132 dogs presenting with non-traumatic haemoabdomen, quality of life was the most important decision factor for 92% of owners, ahead of risk of cancer (57%) and time remaining with their pet (56%) - and 26% of owners second-guessed or were unsure of their decision afterwards. Score quality of life at baseline and at fixed points, with the same instrument each time. Then write down, at the start, what 'this is not working' will look like: which specific signs, at what score, over how many days. An owner who was given the stopping rule in advance is far less likely to experience decisional regret, and far less likely to feel they were sold something.
Named products: No drug. CORQ, the Lynch cancer HRQL questionnaire, plus a written stopping rule in the record and in the owner's hands.
Tier 2. The owner-priority and regret figures are from a 132-dog owner survey with retrospective records - observational, single condition, but directly about the decision this step governs. The instrument evidence is psychometric validation work, not efficacy work - see the monitoring section. No trial showing that pre-agreed stopping rules improve outcomes in veterinary oncology was located; the rationale is the documented regret rate plus the caregiver-burden literature.
Support the owner deliberately - caregiver burden is present before the diagnosis is even confirmed
Controlled trial in this speciesIn 164 owners of pets attending a veterinary oncology service with SUSPECTED cancer, caregiver burden was already present at the earliest stage, before diagnosis, and correlated with stress (r=0.40, P<.001), depression symptoms (r=0.50, P<.001) and lower owner quality of life (r=0.39, P<.001). The correlates of burden were life-disruptive treatment schedules and difficulty adhering to medication routines - both of which are design choices a clinic can change. In general veterinary clients, burden is predicted not only by the frequency of the animal's signs but by the client's sense of control, and the authors conclude that supporting that sense of control may relieve burden even when the animal's condition cannot be improved. This is also a clinical safety issue: controlling for the animal's quality of life, only caregiver burden and income independently predicted steps toward a euthanasia decision. Practical actions: simplify the dosing schedule, consolidate visits, write everything down, name one point of contact, and ask the owner directly how they are coping.
Named products: No drug. Schedule design, written instructions, single named contact, direct enquiry about owner coping, referral to support resources.
Tier 2-3. Cross-sectional correlational studies in the right population - owners of dogs and cats with suspected or diagnosed cancer, and general veterinary clients. Correlational, not interventional: no trial showing that a specific burden-reduction intervention changes animal or owner outcomes was located. The findings are robust enough to design around and should not be stated as proven causation.
Never let an unproven adjunct displace a proven therapy - there is in-species evidence that this costs life
Controlled trial in this speciesThis is the most important sentence on the page for a company that sells adjuncts. In a prospective study of 101 dogs after splenectomy for splenic haemangiosarcoma, owners chose between Coriolus versicolor polysaccharopeptide (I'm-Yunity, PSP) alone or adjuvant doxorubicin, and those choosing doxorubicin were blindly randomised to PSP or placebo alongside it. Adding PSP to doxorubicin did not improve survival. Worse, female dogs treated with PSP ALONE had significantly reduced survival compared with females receiving doxorubicin plus placebo (HR 0.21; P=.004). An adjunct that is merely ineffective costs money. An adjunct that is taken INSTEAD OF effective therapy costs time the dog does not have. Every adjunct discussion must start by confirming that the primary therapy is not being displaced.
Named products: No drug. Coriolus versicolor polysaccharopeptide (I'm-Yunity) is a supplement, not an approved veterinary drug, and showed no survival benefit added to doxorubicin.
Tier 2, and the result is a harm signal. Prospective, n=101, with a blinded randomised comparison inside the doxorubicin arm; the PSP-alone arm was owner-selected and therefore not randomised against chemotherapy, so the female-dog survival difference is confounded by selection and must be reported as an association, not as proof that PSP shortens life. Even read conservatively it is the best in-species evidence available on the cost of substitution, and the blinded add-on comparison cleanly showed no benefit.
Protect the people - cytotoxic handling, and the team training that makes it real
Approved / guideline-backedThe AAHA Oncology Guidelines emphasise methods to protect patient, team and client safety in handling cytotoxic chemotherapeutics, and the 2026 edition explicitly encourages strengthening the training, education and responsibilities of veterinary technicians as part of that. Practical content: closed-system transfer devices, designated preparation area, personal protective equipment, spill kit, written handling SOP, pregnancy policy, and owner instructions for handling urine, faeces and vomit at home for the labelled excretion period of the specific drug. The TANOVEA label states the drug is cytotoxic and may cause birth defects and affect fertility in males - that class of warning belongs in the client handout, not only in the pharmacy.
Named products: No drug. Closed-system transfer devices, PPE, written SOP, client handling handout per the specific product label.
Tier 1 guideline. AAHA 2016 and 2026 both make cytotoxic handling precautions a named component of oncology case management; the specific excretion-period instructions come from each product's own FDA-approved label and differ by drug.
AAHA Oncology Guidelines for Dogs and Cats (2026), with the 2022 AAHA Pain Management Guidelines as the analgesia companion — American Animal Hospital Association
How it is diagnosed
- A tissue diagnosis comes first. The 2016 and 2026 AAHA Oncology Guidelines both hold that determination of tumour type by histologic examination of a biopsy sample should be the basis for all subsequent steps in case management - cytology, histology, or both. Guessing from an X-ray or an ultrasound picture is not a diagnosis and does not license treatment.
- Fine-needle aspirate for cytology as the low-cost, low-morbidity first pass on an accessible mass; incisional or needle-core biopsy for histology when cytology is non-diagnostic or when grade is needed to plan surgery.
- Grade as well as type. The AAHA guidelines make the choice of therapeutic modality a function of tumour type, histologic grade AND stage - a grade is not a formality, it changes the surgical margin and whether chemotherapy is offered.
- Stage the patient before treating: thoracic imaging, abdominal imaging, and regional lymph node sampling per the 2026 AAHA Oncology Guidelines. Lymph node sampling is specifically named - palpating a node is not staging it.
- Baseline CBC, serum biochemistry and urinalysis before any cytotoxic therapy, so that later myelosuppression, renal or hepatic change can be attributed rather than guessed at.
- Baseline body weight, body condition score and muscle condition score, recorded numerically. Cancer-associated weight and muscle loss cannot be tracked without a starting number.
- A baseline quality-of-life score, recorded on a validated instrument before treatment begins - see the monitoring section. Impressionistic recall of how the dog was a month ago is the single least reliable input into a treatment decision.
- Refer or consult. The 2026 AAHA Oncology Guidelines are explicit that collaboration between general practitioners and veterinary oncologists optimises patient care and that referral is often necessary, especially in complex cases; they cover the tools that aid referral and consultation.
Where a biologic fits
Our own product, graded by the same rule
There is no published controlled clinical trial of any stem cell, exosome or peptide product as a treatment or adjunct treatment for cancer in dogs, no animal cell- or exosome-based product is FDA-approved for any species, and because mesenchymal stem cells are documented in laboratory work to be capable of promoting tumour progression as well as suppressing it, the honest conclusion is that these products have no role in the care of a dog with cancer - so PetSmartMeds does not offer, recommend or supply them for a dog with a diagnosed or suspected tumour, and the supportive care that does have evidence behind it is analgesia, antiemesis, appetite and weight maintenance, myelosuppression monitoring and formal quality-of-life measurement.
What exists
Set out in full, because the honest answer here is short and the reasons for it are not. CELL THERAPY IN CANINE CANCER. No controlled clinical trial of mesenchymal stem cells as treatment or as adjunct treatment for any cancer in dogs was located. The nearest canine safety datum is a retrospective review of 40 client-owned dogs given intravenous allogeneic adipose-derived MSCs between 2012 and 2018 for a range of underlying diseases, followed for at least 6 months with physical examination, blood tests and radiographs, in which no significant adverse effects were detected and no new neoplasms were observed (Cho et al. 2024, BMC Vet Res 20:375, PMID 39174969, DOI 10.1186/s12917-024-04216-3). Read it precisely: n=40, retrospective, 6 months, in dogs treated for NON-cancer conditions, with no control group. It is modest reassurance that IV MSC infusion did not cause tumours in a small cohort over half a year. It is not evidence about giving MSCs to a dog that already has a tumour. THE MECHANISTIC REASON FOR CAUTION IS SPECIFIC TO THIS INDICATION. Mesenchymal stromal cells are documented to play a dual role in cancer, with the ability to limit OR promote tumour progression. They interact with the tumour microenvironment, modulate tumour cell behaviour, and are described as promoting distant metastasis formation through secreted mediators, regulation of cell-cell interactions and modulation of the immune response, including differentiation into cancer-associated fibroblasts (Slama et al. 2023, Int J Mol Sci 24(17):13511, PMID 37686315, DOI 10.3390/ijms241713511). Species label: that review is human and laboratory work, not canine clinical work, and it also describes anti-tumour effects and interest in MSCs as delivery vehicles. The point is not that MSCs are proven to worsen canine cancer. The point is that in a tumour-bearing patient the uncertainty runs in BOTH directions, which is categorically different from the uncertainty in, say, osteoarthritis. LONG-TERM TUMORIGENICITY IS OPEN, NOT CLOSED. A veterinary review of MSC tumorigenic risk concludes MSCs carry lower tumour-associated risk than embryonic or induced pluripotent stem cells and that high-dose MSCs injected into nude mice did not form tumours, while stating plainly that 'a direct confirmation of whether tumors originate from stem cells or host cells is not easily achievable' (Jeung et al. 2024, Animals, DOI 10.3390/ani14070994). A 2025 cross-species veterinary MSC review lists potential adverse effects including tumorigenicity as remaining under investigation (Morawska-Kozlowska et al. 2025, Animals, DOI 10.3390/ani15081175). The EMA maintains a dedicated scientific guideline titled 'Allogenic mesenchymal stem cell-based products for veterinary use: specific questions on tumorigenicity.' The defensible formulation is: no tumours attributable to MSC therapy have been reported in the published canine or feline clinical literature, and long-term tumorigenicity has not been formally excluded. Never 'these products do not cause cancer.' EXOSOMES AND EXTRACELLULAR VESICLES IN CANINE CANCER. Nothing. A systematic search of the canine and feline EV literature located no in-vivo clinical efficacy study of any exosome or EV product for any cancer indication in dogs. The one canine oncology exosome reference that surfaced - a transmissible venereal tumour study attributed to Ramos-Zayas - was available only as a secondhand citation inside a review, was never retrieved as a primary paper, and is recorded in our own research corpus as 'Unverified. Do not cite.' It is not cited here and must not be cited anywhere. PEPTIDES IN CANINE CANCER. Nothing, and in one respect worse than nothing. No peptide in the MicroAmino catalogue has controlled efficacy evidence for any indication in dogs, cats or horses, and none has any canine oncology evidence at all. BPC-157 has beagle pharmacokinetic data and no canine efficacy data; TB-500 (thymosin beta-4) has essentially nothing in companion animals and is FEI-banned. The growth-axis peptides in that catalogue - IGF-1 LR3, CJC-1295, ipamorelin, GHRP-6, sermorelin, hexarelin - are anabolic and mitogenic agents with no legitimate veterinary indication, all swept by the FEI's 'Growth Hormone or analogues' and 'Growth Factors' prohibitions, and long-arg3 IGF-1 in particular is recorded in our corpus as a designer anabolic with mitogenic risk and a hard no. Administering a mitogenic agent to an animal with a proliferative disease is the wrong direction of travel and there is no evidence base that could be produced to justify it. IMMUNE PRIVILEGE IS NOT A DEFENSIBLE CLAIM IN ANY INDICATION. In a study of intra-articular MSC administration in dogs, BOTH equine and canine MSCs raised antibody titres in the recipients (Punzon et al. 2023, Front Vet Sci 10:1098029, PMID 37266387). Safety was nonetheless acceptable, but the phrase 'immune-privileged' or any implication that these cells are immune-invisible is contradicted by in-species data and must never appear. WHAT AN APPROVED CELL PRODUCT ACTUALLY LOOKS LIKE, FOR CONTRAST. DogStem (EMA EMEA/V/C/005829) is an authorised veterinary medicinal product using EQUINE umbilical-cord MSCs in DOGS - a xenogeneic product - and it reported 51% of treated dogs versus 5% of placebo meeting a force-plate gait endpoint at 8 weeks. Its indication is OSTEOARTHRITIS. It is not authorised for cancer, was not studied in cancer, and its authorisation is not a predicate for any other cell or cell-free product. Supporting canine OA cell-therapy trials exist at the level of a handful of small randomised studies (for example Punzon et al. 2022, JAVMA, 80 client-owned dogs with elbow or hip OA, PMID 36198051). That is the ceiling of the evidence in this whole category, it belongs to a different disease, and even there it is small and largely sponsor-affiliated.
What has not been shown
Stated plainly so it cannot be read the other way round. 1. There is NO published controlled clinical trial of any mesenchymal stem cell, exosome, extracellular vesicle, secretome or peptide product as a treatment or adjunct treatment for ANY cancer in dogs. Not one. Not for lymphoma, not for osteosarcoma, not for mast cell tumour, not for haemangiosarcoma, not for melanoma, not for carcinoma. 2. There is no evidence that any of these products improves pain, appetite, body weight, nausea, quality of life, disease-free interval or survival in a dog with cancer. No such endpoint has been tested. 3. There is no evidence that any of these products is SAFE in a dog with an active tumour. The only canine MSC neoplasia-surveillance data located (n=40, 6 months) was in dogs treated for other diseases. A cancer patient was not the study population. 4. No animal cell-, tissue- or exosome-based product is FDA-approved for any species for any indication. FDA states verbatim that 'Currently, no ACTPs are FDA-approved' and that 'It is illegal to market an unapproved ACTP because it hasn't gone through the required FDA pre-market review and approval process.' These products are unapproved new animal drugs in the United States. A Colombian entity does not change US marketing law for US-directed promotion. 5. No exosome product has any published manufacturing quality standard in veterinary use, and there is no accepted characterisation standard that a purchasing clinic could hold a supplier to. 6. Long-term tumorigenicity of allogeneic veterinary MSC products has NOT been formally excluded. The EMA maintains a dedicated guideline on exactly that question. 7. There is no mechanism by which we could in good faith frame these products as 'gentle,' 'natural,' 'supportive' or 'low-risk' for a cancer patient. The relevant laboratory biology says the risk is bidirectional, and bidirectional risk in an animal with a proliferative disease is not a low-risk profile.
Sources
- Cho 2024 - the only canine MSC study that actively surveilled for new neoplasms; n=40, retrospective, 6 months, non-cancer patients — Cho HS, Song WJ, Nam A, Li Q, An JH, Ahn JO, Kim HT, Park SM, Ryu MO, Kim MC, Kim JH, Youn HY. Intravenous injection of allogenic canine mesenchymal stem cells in 40 client-owned dogs: a safety assessment in veterinary clinical trials. BMC Vet Res. 2024;20(1):375. PMID 39174969; PMC11340047; DOI 10.1186/s12917-024-04216-3. https://doi.org/10.1186/s12917-024-04216-3
- Slama 2023 - MSC dual role in cancer; the mechanistic reason to decline this indication. HUMAN AND LABORATORY REVIEW, not canine clinical data — Slama Y, Ah-Pine F, Khettab M, Arcambal A, Begue M, Dutheil F, Gasque P. The Dual Role of Mesenchymal Stem Cells in Cancer Pathophysiology: Pro-Tumorigenic Effects versus Therapeutic Potential. Int J Mol Sci. 2023;24(17):13511. PMID 37686315; PMC10488262; DOI 10.3390/ijms241713511. https://doi.org/10.3390/ijms241713511
- Punzon 2023 - both equine and canine MSCs RAISED antibody titres in dogs; 'immune-privileged' is not a defensible claim — Punzon E, et al. Front Vet Sci. 2023;10:1098029. PMID 37266387. https://pubmed.ncbi.nlm.nih.gov/37266387/
- Punzon 2022 - the best canine MSC RCT in the whole category, and its indication is OSTEOARTHRITIS, not cancer; xenogeneic equine UC-MSC, 80 client-owned dogs — Punzon E, et al. Equine umbilical cord mesenchymal stem cells for intra-articular treatment of elbow or hip osteoarthritis in dogs: a multicentric, double-blinded, parallel, randomised, placebo-controlled study. J Am Vet Med Assoc. 2022. PMID 36198051; DOI 10.2460/javma.22.06.0237. https://doi.org/10.2460/javma.22.06.0237
- Jeung 2024 - veterinary MSC tumorigenic risk review; lower risk than ESC/iPSC but origin of any tumour 'not easily achievable' to confirm — Jeung S, et al. Animals. 2024;14(7):994. DOI 10.3390/ani14070994. https://doi.org/10.3390/ani14070994
- Morawska-Kozlowska 2025 - cross-species veterinary MSC review listing tumorigenicity as an open adverse-effect question — Morawska-Kozlowska M, et al. Animals. 2025;15(8):1175. DOI 10.3390/ani15081175. https://doi.org/10.3390/ani15081175
- EMA - dedicated scientific guideline on tumorigenicity of allogeneic veterinary MSC products; proof the question is open at regulator level — European Medicines Agency. Allogenic mesenchymal stem cell-based products for veterinary use: specific questions on tumorigenicity. https://www.ema.europa.eu/en/allogenic-mesenchymal-stem-cell-bas
- FDA - 'Currently, no ACTPs are FDA-approved'; 'It is illegal to market an unapproved ACTP'. Verified by direct fetch, quoted verbatim — US Food and Drug Administration. FDA's Role in Veterinary Regenerative Medicine. Governing guidance: CVM GFI #218, Cell-Based Products for Animal Use, June 2015. https://www.fda.gov/animal-veterinary/cell-and-tissue-products-a
- Gedney 2022 - in-species evidence of what substitution costs; PSP added to doxorubicin gave no benefit, and PSP alone in females was associated with significantly shorter survival — Gedney A, Salah P, Mahoney JA, Krick E, Martins R, Scavello H, Lenz JA, Atherton MJ. Evaluation of the anti-tumour activity of Coriolus versicolor polysaccharopeptide (I'm-Yunity) alone or in combination with doxorubicin for canine splenic hemangiosarcoma. Vet Comp Oncol. 2022;20(3):688-696. PMID 35442554; DOI 10.1111/vco.12823. https://doi.org/10.1111/vco.12823
- The two canine monoclonal antibodies are the legitimate 'biologic' story for this brand - and neither is indicated for cancer — Bedinvetmab (Librela), caninised anti-NGF monoclonal antibody, FDA-approved 5 May 2023 for control of osteoarthritis pain in dogs; FDA Freedom of Information Summary. Lokivetmab (Cytopoint), caninised anti-IL-31 monoclonal antibody, USDA APHIS Center for Veterinary Biologics licensed December 2016 for pruritus associated with atopic dermatitis in dogs. Neither has a cancer indication. Do not conflate the FDA and USDA pathways. https://animaldrugsatfda.fda.gov/adafda/app/search/public/docume
Tracking response
How you know whether it is working
Clinicians track this with CORQ - the Canine Owner-Reported Quality of Life questionnaire. It is the right instrument for this protocol for three reasons: it was developed and validated specifically in dogs with CANCER, it measures observable behaviour rather than asking owners to interpret symptoms, and it is the only instrument in this field with a peer-reviewed Spanish validation. Verified structure: 17 items on observable behaviours, assigned to four factors - vitality, companionship, pain and mobility. Developed from key-informant interviews with owners of 25 dogs, then reliability and validity tested in owners of 90 dogs with cancer; Cronbach's alpha 0.68 to 0.90, correlations with a global quality-of-life visual analogue scale r=0.49 to 0.71, with good test-retest reliability and responsiveness. Honest caveat from the authors themselves: 'Several items pertaining to physical symptoms performed poorly and were omitted.' CORQ deliberately does not measure symptoms, so it must be paired with clinician-side adverse event grading (VCOG-CTCAE v2) and with body weight, body condition score and muscle condition score. A second cancer-specific instrument exists and was used in the STELFONTA registration study - Lynch et al., a health-related quality-of-life questionnaire for dogs and cats with cancer (PMID 21848620) - and is a reasonable alternative where CORQ licensing cannot be obtained. No published minimal important difference for CORQ was located: do not invent a change threshold. Track direction and consistency across visits, and use the owner's own nominated activities as the anchor..
Development: Giuffrida MA, Brown DC, Ellenberg SS, Farrar JT. Development and psychometric testing of the Canine Owner-Reported Quality of Life questionnaire, an instrument designed to measure quality of life in dogs with cancer. J Am Vet Med Assoc. 2018;252(9):1073-1083. PMID 29641337; DOI 10.2460/javma.252.9.1073. Spanish validation: Fuertes-Recuero M, Rodriguez-Gonzalez P, Suarez-Redondo M, Portero M, Yzuel A, Penelo S, Perez C, Martinez de Merlo E, Giuffrida MA, Ortiz-Diez G. Cultural adaptation and psychometric properties of the canine owner-reported quality of life questionnaire (CORQ) for assessing quality of life in dogs with cancer. Vet J. 2026;315:106503. PMID 41314459; DOI 10.1016/j.tvjl.2025.106503 - translated and culturally adapted following WHO guidelines, with high internal consistency (Cronbach's alpha 0.841 for vitality and 0.946 for wellness) and significant correlations with established QoL measures; note the Spanish factor structure is described with 'vitality' and 'wellness' rather than the four English factors, so do NOT assume the English scoring transfers. Alternative: Lynch S, Savary-Bataille K, Leeuw B, Argyle DJ. Development of a questionnaire assessing health-related quality-of-life in dogs and cats with cancer. Vet Comp Oncol. 2011;9(3):172-82. PMID 21848620. Clinician-side adverse event grading: LeBlanc AK, et al. VCOG-CTCAE v2. Vet Comp Oncol. 2021;19(2):311-352. PMID 33427378; DOI 10.1111/vco.12677.
HONEST STATUS - DO NOT GUESS AND DO NOT REPRODUCE THE ITEMS. CORQ was developed at the University of Pennsylvania School of Veterinary Medicine, and its Spanish adaptation was published with the original developer (Giuffrida, now at UC Davis) as a co-author, which means that adaptation is authorised rather than a rogue translation. The instrument is third-party copyrighted academic material and written permission should be sought from the rights holder before it is embedded in a commercial monitoring product in either language; the exact licence terms were NOT verified in this research pass and must be confirmed before launch. The Lynch cancer HRQL questionnaire is Wiley-published and carries the same requirement. The HHHHHMM / 'Pawspice' end-of-life scale must NOT be implemented: no psychometric validation study for it was located, and its seven items and 0-10 grid are copyrighted Wiley book content (Villalobos A, Kaplan L, Canine and Feline Geriatric Oncology, palliative care chapter). Link out to it if an end-of-life aid is needed; do not reproduce it. The owner questions below were written fresh for this protocol and deliberately do NOT reproduce CORQ, Lynch or HHHHHMM items - they are a plain-language home check-in, not a validated instrument, and must be labelled as such wherever they appear.
Suggested cadence: Baseline before any treatment starts - this is the single most-skipped step and it makes every later comparison guesswork. Then: CORQ plus body weight, body condition score and muscle condition score at each treatment visit (which for most canine cytotoxic protocols means every 7 to 21 days, and for the TANOVEA-labelled regimen every 21 days for up to five cycles). CBC before every cytotoxic dose, and same-day if the dog becomes unwell between doses. Owner-completed home check-in weekly during the first cycle, when nausea, inappetence and lethargy peak, then at each cycle thereafter. After definitive local therapy with no ongoing chemotherapy, re-score at the first post-operative recheck and then on the restaging interval the tumour type dictates. Two scheduling rules that come from the caregiver-burden evidence rather than the oncology evidence: consolidate visits wherever clinically possible, because life-disruptive treatment schedules and difficult medication routines were the named correlates of owner burden; and record the agreed stopping rule at baseline in the same place as the baseline score, so that the comparison and the decision live together.
Questions you can answer at home
- In the last week, how many days would you call good days for your dog - days you would be happy to repeat? (count them: 0 to 7)
- How is she eating compared with before treatment started? (eating normally / eating but needs coaxing / only eating favourites / barely eating / not eating at all)
- Has she vomited or had diarrhoea since the last visit, and if so on how many separate days?
- Does she still do the two or three things you told us she loves most - the greeting at the door, the toy, the sofa, the particular walk? (all of them / some of them / none of them)
- Does she seem sore or uncomfortable, and if so when is it worst - getting up, during a walk, at night, or all the time?
- How is she in herself - does she still seem like your dog, or has something changed in how she is with you?
- How are YOU doing with the schedule and the medicines this week - is anything about the plan too hard to keep up?
Build a profile for your pet
Tell us what you are dealing with and the site will show you only what applies.